WO1994008538A1 - Membrane oculaire medicinale et son procede de production - Google Patents

Membrane oculaire medicinale et son procede de production Download PDF

Info

Publication number
WO1994008538A1
WO1994008538A1 PCT/RU1993/000242 RU9300242W WO9408538A1 WO 1994008538 A1 WO1994008538 A1 WO 1994008538A1 RU 9300242 W RU9300242 W RU 9300242W WO 9408538 A1 WO9408538 A1 WO 9408538A1
Authority
WO
WIPO (PCT)
Prior art keywords
solution
membrane
eye
film
emoxipin
Prior art date
Application number
PCT/RU1993/000242
Other languages
English (en)
Russian (ru)
Inventor
Alexander Dmitrievich Romaschenko
Original Assignee
Aktsionernoe Obschestvo 'olvik'
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aktsionernoe Obschestvo 'olvik' filed Critical Aktsionernoe Obschestvo 'olvik'
Publication of WO1994008538A1 publication Critical patent/WO1994008538A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/14—Eye parts, e.g. lenses, corneal implants; Implanting instruments specially adapted therefor; Artificial eyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants

Definitions

  • the invention is not limited to the field of medicine, in particular for ophthalmology, and may be used for the treatment of intraocular infections.
  • the known drug when used, has the following disadvantages: the medication in most cases and in the majority of cases causes an allergic reaction. The reactions are manifested in the form of a process, an increase in the temperature, and hypoxia of the eye. The drug is very toxic, which leads to its pronounced effect on the chain and the visual disturbance of the eyeball, and the treatment of chronic diseases.
  • the introduction of a simple test method is a very painful procedure for a painful and, most importantly, troublesome condition.
  • ophthalmic films on the basis of acrylamide, vinylpropylene and ethylacrylate with ethylene sulfide, are taken as the main film. (I. ⁇ .
  • HFL ophthalmic film
  • the eye film is a direct film containing an absorbing drug and an acceptable base that contains external layers with the inclusion
  • Emoksipin has another area of application.
  • the mechanism of its action is complex. It includes a retentive and fibro-political component.
  • the protection of continuous waste is ensured due to the anti-oxidative effects of it, the multiplication of mucks and whistles. When it is removed, the level of oxidized oxidation of lipids is reduced, and the mechanism of absorption of
  • both drugs are included in a simple basic case.
  • the film is produced by loading food or using a ribbon of a fully-fledged machine by using a recent hire.
  • the treatment of internal ocular lesions with the use of ocular hemolytic film is performed as follows.
  • the stylish eye film is placed in the conjunctiva
  • 30 ophthalmic film consists of: direct reaction - 2-6.7; emo ⁇ -si ⁇ ina - 6.7-33.3; the basic base is 89.3-60 mass%.
  • Example I Methods for the production of a hegolitic eye film
  • Production of a basic film is traditional. In general, 89.3 g of water are dispersed in 455.4 g of distilled water at a temperature of 40-60 °. The resulting displacement of 1.0 g (6.7 mass.) Of emoxipine and the intermixing of the complete solution, I. The dividers are divided into two parts ( ⁇ and B).
  • Example 2 A reasonable amount in the amount of 90 g (60 mass.) Grows in 910 g of distilled water before
  • Example 3 An approximate basis in the amount of 70 g
  • the vision of the left eye is the correct illumination. There is no-eye pressure equal to +1.
  • the vision of the left eye 0.9-1.0.
  • the left eye is quick, the part is very sharp, the front camera is of medium depth, its moisture is clean. Deep-lying environments are not changed. On the power program - changes in the chain are not shared.
  • the drug does not cause ayalergic and harmful effects, are easily transmitted by patients.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Cardiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'essence de l'invention réside dans une membrane oculaire médicinale composée d'une base polymère biodégradable, d'un antioxydant et d'une enzyme thrombolytique, les composés étant agencés en couches, une couche de l'enzyme thrombolytique telle que la streptodécase étant placée entre des couches d'antioxydant, par exemple l'émoxipine. On produit la membrane par application d'une solution d'émoxipine dans le polymère à la base et par séchage de celui-ci dans un flux d'air chaud, puis par application de façon similaire d'une solution d'une streptodécase dans le polymère et d'une autre couche de la solution d'émoxipine. La membrane est ensuite séchée, façonnée, conditionnée et stérilisée. La membrane ainsi produite est multifonctionnelle et agit pendant une période prolongée.
PCT/RU1993/000242 1992-10-22 1993-10-21 Membrane oculaire medicinale et son procede de production WO1994008538A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU92001988/14 1992-10-22
RU92198814 1992-10-22

Publications (1)

Publication Number Publication Date
WO1994008538A1 true WO1994008538A1 (fr) 1994-04-28

Family

ID=20135208

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/RU1993/000242 WO1994008538A1 (fr) 1992-10-22 1993-10-21 Membrane oculaire medicinale et son procede de production

Country Status (1)

Country Link
WO (1) WO1994008538A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2248516A1 (fr) * 2009-05-06 2010-11-10 Sanovel Ilac Sanayi ve Ticaret A.S. Compositions pharmaceutiques d'emoxypine à désintégration orale

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1018634A1 (ru) * 1981-11-17 1983-05-23 Всесоюзный кардиологический научный центр АМН СССР Способ лечени внутриглазных кровоизли ний
US4990337A (en) * 1988-01-29 1991-02-05 Sankyo Company Limited Cyclosporin formulations of mono or diglyceride fatty acid
US5164188A (en) * 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1018634A1 (ru) * 1981-11-17 1983-05-23 Всесоюзный кардиологический научный центр АМН СССР Способ лечени внутриглазных кровоизли ний
US4990337A (en) * 1988-01-29 1991-02-05 Sankyo Company Limited Cyclosporin formulations of mono or diglyceride fatty acid
US5164188A (en) * 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
I.A. MURAVIEV, "Technologia Lekartstvennykh Form", 1988, Meditsina, (Moscow), pages 400-402. *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2248516A1 (fr) * 2009-05-06 2010-11-10 Sanovel Ilac Sanayi ve Ticaret A.S. Compositions pharmaceutiques d'emoxypine à désintégration orale
TR200903548A1 (tr) * 2009-05-06 2010-11-22 Sanovel İlaç San. Ve Ti̇c. A.Ş. Oral yolla dağılan emoksipin bileşimleri

Similar Documents

Publication Publication Date Title
US3826258A (en) Gradual release medicine carrier
CN103720524A (zh) 一种制作灵长类动物干性年龄相关性黄斑变性疾病模型的方法
WO1994008538A1 (fr) Membrane oculaire medicinale et son procede de production
EP1121929B1 (fr) Composition contenant des sels di- et trisodiques de l'echinochrome pour le traitement des troubles oculaires
Yates et al. Engineering development of therapeutic systems: a new class of dosage forms for the controlled delivery of drugs
RU2056819C1 (ru) Глазная лекарственная пленка и способ ее изготовления
Kaplan The allantoin treatment of ulcers
Olson et al. Polyvinyl alcohol as a protective coating on intraocular lenses
CN102302514A (zh) 猪血去蛋白提取物凝胶剂及其制备方法
SU904697A1 (ru) Способ профилактики и лечени инфекционных заболеваний глаз
Wood A System of Ophthalmic Therapeutics: Being a Complete Work on the Non-operative Treatment, Including the Prophylaxis, of Diseases of the Eye
Wetarini Ocular superglue injury: a case report and review of literature
RU2090166C1 (ru) Способ лечения десцеметоцеле
RU2090165C1 (ru) Способ лечения поражений роговицы
SU1018634A1 (ru) Способ лечени внутриглазных кровоизли ний
RU2329018C1 (ru) Способ лечения при проникающих ранениях органа зрения
RU2008858C1 (ru) Способ введения лекарственных препаратов
RU2575590C1 (ru) Способ лечения рецидивирующих эрозий роговицы
Kinsey for patients to treat themselves for hypertension with small daily doses of magnesium sulfate, sometimes combined in
RU2127571C1 (ru) Способ лечения воспалительных заболеваний роговицы
RU2314793C2 (ru) Способ получения глазных пленок
RU2230566C1 (ru) Способ профилактики осложнений герпес-вирусной инфекции при повреждениях роговицы
McCutchen A neurologist looks at death
Rutherford PROGRESS IN MEDICAL AND IN SURGICAL TREATMENT IN OPHTHALMOLOGY 1929-1930
RU2196556C2 (ru) Способ лечения органических и функциональных заболеваний сетчатки

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA